Urocit-K (potassium citrate) Information for Health Professionals

Urocit^®-K inhibits stone formation with a broad range of efficacy

Urocit^®-K is indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.

Urocit^®-K is effective in:
Metabolic Cause	Stone Composition
hypocitraturia	calcium oxalate
hyperuricosuria	calcium oxalate
idiopathic uric acid nephrolithiasis	uric acid
hypercalciuria	calcium oxalate
undue urinary acidity	uric acid
renal tubular acidosis	calcium oxalate
Table 1

Urocit^®-K increases urinary citrate and urinary pH^1-3

Urocit^®-K alkalinizes the urine. The citrate moiety, which is largely oxidized, is absorbed while the K ion remains, leaving an alkali load. The alkali load increases urinary citrate (inhibiting crystallization) and urinary pH (contributing to retardation of crystallization of calcium salts and inhibition of uric acid crystallization). Urocit^®-K decreases urinary saturation of calcium oxalate and inhibits both calcium oxalate and its crystallization.

Urocit^®-K inhibits stone formation in more than 90% of patients^3,7,8

Urocit^®-K produces remission (cessation of stone formation) in over 70% of patients.^3,7,8


	Renal Tubular Acidosis	Chronic Diarrheal Syndrome	Idiopathic Hypocitraturia	Uric Acid Stones
Pre-Treatment Duration (yr/pt)	3	3	3	3
Stone Formation Rate (no./yr)	39.3	4.69	2.11	1.20
Treatment Duration (yr/pt)	2.83	3.2	2.13	2.78
Stone Formation Rate (no./yr)	0^*	0.71^*	0.28^*	0.01^*
Remission (%)	100	70	89	94
Reduced Stone Formation Rate (%)	100	90	100	100
Urocit^®-K is contraindicated in patients with hyperkalemia and/or renal insufficiency. * p<0.01				Table 2

This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.